ARCHIMED completes acquisition of Standard BioTools' microfluidics business

• Archimed has completed its acquisition of Standard BioTools' microfluidics business, a November 10, 2026 update showed.
• The genomic tools business will operate independently as Biomark Scientific, with plans to expand internationally and invest in innovation.
• The acquisition was completed through MED IV, which closed at €1.5 billion in September, three times oversubscribed.
• A dedicated leadership team will be installed over the coming months as the business establishes standalone operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archimed SAS published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.